174
Participants
Start Date
July 31, 2011
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
Ferinject (ferric carboxymaltose)
Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
Standard of Care
Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
University Medical Center Groningen, Groningen
Lead Sponsor
Vifor Pharma
INDUSTRY